KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B.

Yanhang Gao, Xinrui Wang, Zhongfeng Wang, Fei Kong, Lvfeng Yao, Weidong Liu, Jia Shang, Yunsong Yu, Weifeng Zhao, Jinlin Hou, Shuangsuo Dang, Shufen Yuan, Guoxin Hu, Bei Zhong, Hui Chen, Suling Chen, Xiaoping Dong, Xiangping Xie, Zhenguo Liu, Zong Zhang, Xinwen Song, Qing Mao, Yongfang Jiang, Chenxin Meng, Fangqi Ge, Zhijun Su, Qianguo Mao, Yichun Bai, Lei Yu, Youwen Tan, Huizhen Fan, Zhiyong Jiao, Xihua Fu, Liang Hong, Yuanyuan Xu, Xuebing Yan, Jinfeng Liu, Yufeng Gao, Hainv Gao, Guangxia Chen, Hongguang Qu, Hesong Cui, Shihong Wu, Xiaobo Lu, Zhihong Liu, Fengjun Liu, Xiangjun Li, Shuilin Sun, Guofeng Ding, Tao Han, Xiaozhong Wang, Wenhai Zhao, Mingque Xiang, Xuebing Chen, Wenyan He, Shuang Lu, Wenting Zeng, Qinming Hu, Dengke Zhang, Weili Jin, Daidi Wang, Yuan Wang, Chi Zhang, Xiuhong Wen, Zhongqiang Gao, Leiyan Lv, Kangxin Yu, GuangMing Li, Guoqiang Zhang, Guicheng Wu, Junqi Niu

Hepatology 10.1097/HEP.0000000000001754

PMID41945711
PMCID-
DOI10.1097/HEP.0000000000001754
发表日期2026-04-07
摘要

摘要

BACKGROUND AND AIMS: Pradefovir mesylate is a novel liver-targeting prodrug of adefovir developed using HepDirect technology. We report that the phase 3 trial is to compare the efficacy and safety of pradefovir versus tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB). APPROACH AND RESULTS: This ongoing randomized, double-blind, non-inferiority, phase 3 study was conducted at 58 sites in China. Patients with CHB were randomly assigned (2:1) to receive either 45 mg daily pradefovir or 300 mg daily TDF with a matching placebo. The primary efficacy endpoint was defined as the proportion of patients whose HBV DNA level was <29 IU/mL at week 48. All participants who received at least 1 dose of the study drug were included in efficacy and safety analyses with pre-specified renal and bone endpoints at week 96. A total of 1170 patients were screened during the study, and 908 patients received the study drug. At week 48, viral suppression (HBV DNA <29 IU/mL) rates of pradefovir were non-inferior to TDF in HBeAg-positive [-1.8% (95% CI: -9.7 to 6.1)] and HBeAg-negative [2.6% (95% CI: -5.1 to 10.3)] patients, using a non-inferiority margin of -12%. By week 96, HBeAg-positive patients showed significantly greater HBsAg decline (≥1 log 10 IU/mL) with pradefovir (39.3% vs. 29.9%). Pradefovir demonstrated a more favorable safety profile at week 96, including significantly fewer drug-related adverse events (58.6% vs. 71.9%), improved bone/renal safety, and a lower incidence of elevated creatine phosphokinase-MB. CONCLUSIONS: Pradefovir should be a highly recommended treatment option for adult patients with CHB.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。